Microba Life Sciences unveiled initial data from the Phase 1 clinical trial of MAP 315, its lead drug candidate in the inflammatory bowel disease therapeutic program.

The results demonstrate a robust safety and tolerability profile for MAP 315, supporting its ongoing clinical development.

The Phase 1 trial enrolled 32 participants, and ongoing metagenomic analysis confirmed the delivery of live MAP 315 into the gastrointestinal tract.

The results and recent preclinical data strengthen the case for advancing MAP 315 as a potential treatment for ulcerative colitis, a condition affecting over seven million people globally.